Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters, M Price, T Cervantes, A Sobrero, A Ducreux, M Hotko, Y André, T Chan, E Lordick, F Punt, C
Peeters, M
Price, T
Cervantes, A
Sobrero, A
Ducreux, M
Hotko, Y
André, T
Chan, E
Lordick, F
Punt, C
Citations
Altmetric:
Abstract
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.
Description
Date
2010-11-01
Publisher
Collections
Keywords
Anticancerous Combined Chemotherapy Protocols
Colorectal Cancer
Cancer Staging
Biological Tumour Markers
Colorectal Cancer
Cancer Staging
Biological Tumour Markers
Type
Article
Citation
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. 2010, 28 (31):4706-13 J Clin Oncol